The FDA-approved Mylotarg (gemtuzumab ozogamicin) utilizes an acid-sensitive hydrazone linker to efficiently release the DNA-damaging agent calicheamicin within lysosomes, achieving precise targeting of leukemia cells
For example, in a country like the United States, where rates of people being overweight and obesity are soaring, it stands to reason there may be more people using the medication therapeutically than in another country with lower rates of weight-related conditions
This maintains the cold chain from pharmacy to your door, protecting the compound's integrity before you open the vial
Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94]
Tirzepatide is a dual GIP and GLP-1 receptor agonist, and both receptor systems have characteristics that influence how the body responds to varying drug levels
